Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Barrett Esophagus 4Breast Neoplasms 3Pancreatic Neoplasms 2Lymphoma, B-Cell, Marginal Zone 2Inflammation 2Uterine Cervical Dysplasia 1Triple Negative Breast Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Peripheral Nervous System Diseases 1Obesity 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Hodgkin Disease 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Colorectal Neoplasia 1Chemotherapy Effect 1Breast Neoplasms, Male 1

Interventions

Cisplatin 86Radiotherapy 71Paclitaxel 50Fluorouracil 38Carboplatin 36Drug Therapy 32Neoadjuvant Therapy 23toripalimab 19tislelizumab 18pembrolizumab 17camrelizumab 17Irinotecan 17Esophagectomy 17Surgical Procedures, Operative 16Radiation 16Docetaxel 16sintilimab 15Oxaliplatin 14130-nm albumin-bound paclitaxel 14nimotuzumab 11TP protocol 11S 1 (combination) 11Radiotherapy, Intensity-Modulated 11Cetuximab 11Capecitabine 11Albumin-Bound Paclitaxel 10apatinib 9Leucovorin 9Immune Checkpoint Inhibitors 8nedaplatin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Esophageal Squamous Cell Carcinoma × Omeprazole × Clear all
NCT07016737 2025-06-12

ESO-Nanjing12

Jiangsu Cancer Institute & Hospital

Phase 3 Enrolling by invitation
79 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡